Skip to main content

Bradbury Daniel's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Feb 3, 2023

Accession no.
0001447362-23-000013
Filed
Feb 3, 2023
Trade date
Feb 1-2, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 12 non-derivative transactions. Open-market sales total $687.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bradbury DanielCIK 0001236397Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 1, 2023Common StockSSaleDisposed−7,445$26.98F2−$200,866.1192,094Indirect
Feb 1, 2023Common StockSSaleDisposed−2,481$26.98F2−$66,937.3895,299Indirect
Feb 1, 2023Common StockSSaleDisposed−2,482$26.98F2−$66,964.3695,323Indirect
Feb 1, 2023Common StockSSaleDisposed−4,451$27.51F6−$122,447.01187,643Indirect
Feb 1, 2023Common StockSSaleDisposed−1,484$27.51F6−$40,824.8493,815Indirect
Feb 1, 2023Common StockSSaleDisposed−1,483$27.51F6−$40,797.3393,840Indirect
Feb 2, 2023Common StockSSaleDisposed−2,684$28.55F7−$76,628.2184,959Indirect
Feb 2, 2023Common StockSSaleDisposed−895$28.55F7−$25,552.2592,920Indirect
Feb 2, 2023Common StockSSaleDisposed−895$28.55F7−$25,552.2592,945Indirect
Feb 2, 2023Common StockSSaleDisposed−420$29.12F8−$12,230.4184,539Indirect
Feb 2, 2023Common StockSSaleDisposed−140$29.12F8−$4,076.892,780Indirect
Feb 2, 2023Common StockSSaleDisposed−140$29.12F8−$4,076.892,805Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $26.320 to $27.315, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $27.320 to $27.905, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $28.100 to $29.035, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F8

This transaction was executed in multiple trades at prices ranging from $29.105 to $29.145, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)